Annual General Meeting of Active Biotech AB
MAY 11, 2012 - 02:31 ET
FOR: ACTIVE BIOTECH
LUND, SWEDEN--(Marketwire - May 11, 2012) - The Annual General Meeting of Active Biotech was held on May 10, 2012.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.
In accordance with the Election Committee's proposal, the Board members Mats Arnhög, Peter Hofvenstam, Klas Kärre, Mef Nilbert, Magnhild Sandberg, Peter Sjöstrand and Peter Thelin were re-elected. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board.
Furthermore, in accordance with the Election Committee's proposal, the Meeting resolved that the Election Committee shall be composed of representatives for the three largest owners, as per end of September, 2012, as well as the Chairman of the Board.
The Meeting approved the Board's proposal concerning guidelines for remuneration to the President and other senior executives. The guidelines essentially conform to the principles applied to date.
In accordance with the Board's proposal, the Meeting resolved to authorize the Board, for a period that does not extend past the date of the next Annual General Meeting, to resolve on the issue of not more than six million new shares and/or convertibles with the corresponding dilution effect, with or without pre- emptive rights for the company's shareholders.
Lund, May 11, 2012
Active Biotech AB (publ)
Tomas Leanderson President and CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for Systemic Sclerosis and RhuDex® for RA. Please visit http://www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 08:30 a.m. CET on May 11, 2012.
Annual General Meeting of Active Biotech AB: http://hugin.info/1002/R/1610883/512157.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00